Clonidine and Left Ventricular Dysfunction
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00213902|
Recruitment Status : Withdrawn
First Posted : September 21, 2005
Last Update Posted : November 29, 2007
The objectives of this study are:
- To evaluate the effect of clonidine, a sympathetic modulator, to reverse cardiac remodeling and to improve hemodynamics in diastolic heart failure (DHF).
- To evaluate the effect of clonidine on neurohormones and quality of life in patients with DHF.
The study is a double-blind, placebo-controlled study evaluating the effects of clonidine compared to placebo in patients with DHF. A total of 70 patients with DHF will be randomized in a 1:1 ratio to:
- placebo (n=35) or to
- clonidine (n=35) in a dose of 0.075 mg twice a day for the first 6 weeks followed by uptitration to 0.150 mg twice a day for 6 months.
The primary outcome is the reversion of cardiac remodeling and hemodynamic parameters evaluated by magnetic resonance imaging (MRI) and echocardiography.
|Condition or disease||Phase|
|Ventricular Dysfunction||Phase 2|
|Study Type :||Observational|
|Estimated Enrollment :||70 participants|
|Official Title:||Evaluation of Effects of Central Sympathetic Inhibition in Elderly With Left Ventricular Diastolic Dysfunction and Preserved Ejection Fraction: A Proof-of-Concept Trial With Clonidine|
|Study Start Date :||April 2004|
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00213902
|Principal Investigator:||Pascal Bousquet, MD||Hopitaux Universitaires de Strasbourg|